The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) Consensus Statements on Pre-invasive Vulvar Lesions.
Journal
Journal of lower genital tract disease
ISSN: 1526-0976
Titre abrégé: J Low Genit Tract Dis
Pays: United States
ID NLM: 9704963
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
entrez:
28
6
2022
pubmed:
29
6
2022
medline:
1
7
2022
Statut:
ppublish
Résumé
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) developed consensus statements on pre-invasive vulvar lesions in order to improve the quality of care for patients with vulvar squamous intraepithelial neoplasia, vulvar Paget disease in situ, and melanoma in situ. For differentiated vulvar intraepithelial neoplasia (dVIN), an excisional procedure must always be adopted. For vulvar high-grade squamous intraepithelial lesion (VHSIL), both excisional procedures and ablative ones can be used. The latter can be considered for anatomy and function preservation and must be preceded by several representative biopsies to exclude malignancy. Medical treatment (imiquimod or cidofovir) can be considered for VHSIL. Recent studies favor an approach of using imiquimod in vulvar Paget's disease. Surgery must take into consideration that the extension of the disease is usually wider than what is evident in the skin. A 2 cm margin is usually considered necessary. A wide local excision with 1 cm free surgical margins is recommended for melanoma in situ. Following treatment of pre-invasive vulvar lesions, women should be seen on a regular basis for careful clinical assessment, including biopsy of any suspicious area. Follow-up should be modulated according to the risk of recurrence (type of lesion, patient age and immunological conditions, other associated lower genital tract lesions).
Identifiants
pubmed: 35763611
doi: 10.1097/LGT.0000000000000683
pii: 00128360-202207000-00007
pmc: PMC9232287
doi:
Substances chimiques
Imiquimod
P1QW714R7M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-244Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.
Déclaration de conflit d'intérêts
C.C. served on advisory boards for GSK and MSD and reports support for clinical research from Roche and TherAguiX. D.Q. served on advisory boards for Mimark. E.J. served on advisory boards for MSD and Roche Diagnostics and reports grants for traveling from MSD. J.B. reports support for clinical research from Merck (Galilee Medical Center Research Fund) and was a member of speakers’ bureau for MSD Israel. The other authors declared they have no conflicts of interest.
Références
Wilkinson EJ, Kneale B, Lynch PJ. Report of the ISSVD terminology committee. J Reprod Med Obstet Gynecol 1986;31:973–4.
Sideri M, Jones RW, Wilkinson EJ. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD vulvar oncology subcommittee. J Reprod Med 2005;50:807–10 http://www.ncbi . nlm.nih.gov/pubmed/16419625 .
Darragh TM, Colgan TJ, Cox JT, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16:205–42.
World Health Organization. International classification of diseases for mortality and morbidity statistics (11th Revision), 2018. Available: https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/913387730 .
Bornstein J, Bogliatto F, Haefner HK, et al. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. J Low Genit Tract Dis 2016;20:11–4.
Crum C, Herrington C, McCluggage W. Tumours of the vulva; epithelial tumors. In: WHO classification of tumours of female reproductive organs . Lyon: IARC Press; 2014.
WHO Classification of Tumours Editorial Board. Female genital tumours . 5th ed. Lyon; 2020. https://tumourclassification.iarc.who.int/chapters/34 .
Wilkinson EJ, Brown HM. Vulvar Paget disease of urothelial origin: a report of three cases and a proposed classification of vulvar Paget disease. Hum Pathol 2002;33:549–54.
Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 2018;25:2105–10.
Lebreton M, Carton I, Brousse S, et al. Vulvar intraepithelial neoplasia: classification, epidemiology, diagnosis, and management. J Gynecol Obstet Hum Reprod 2020;49.
Lukasiewicz E, Aractingi S, Flahault A. Incidence et prise en charge des condylomes acuminés externes en médecine générale. Ann Dermatol Venereol 2002;129:991–6 http://www.ncbi.nlm.nih.gov/ pubmed/12442095.
Monsonégo J, Breugelmans J-G, Bouée S. Incidence, prise en charge et coût des condylomes acuminés anogénitaux chez les femmes consultant leur gynécologue en France. Gynécologie Obs Fertil 2007;35:107–13.
van Seters M, van Beurden M, de Craen AJM. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 2005;97:645–51.
Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005;106:1319–26.
Thuijs NB, Beurden M, Bruggink AH, et al. Vulvar intraepithelial neoplasia: incidence and long-term risk of vulvar squamous cell carcinoma. Int J Cancer 2021;148:90–8.
de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013;49:3450–61.
van de Nieuwenhof HP, Massuger LFAG, van der Avoort IAM, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer 2009;45:851–6.
Bodelon C, Madeleine MM, Voigt LF, et al. Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control 2009;20:1779–82.
Clifford GM, Georges D, Shiels MS, et al. A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale. Int J Cancer 2021;148:38–47.
Saleem AM, Paulus JK, Shapter AP, et al. Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm. Obstet Gynecol 2011;117:643–9.
van der Zwan JM, Siesling S, Blokx WAM, et al. Invasive extramammary Paget’s disease and the risk for secondary tumours in Europe. Eur J Surg Oncol 2012;38:214–21.
van der Linden M, Meeuwis KAP, Bulten J, et al. Paget disease of the vulva. Crit Rev Oncol Hematol 2016;101:60–74.
Mendivil AA, Abaid L, Epstein HD, et al. Paget's disease of the vulva: a clinicopathologic institutional review. Int J Clin Oncol 2012;17:569–74.
Karam A, Dorigo O. Treatment outcomes in a large cohort of patients with invasive extramammary Paget's disease. Gynecol Oncol 2012;125:346–51.
Niikura H, Yoshida H, Ito K, et al. Paget's disease of the vulva: clinicopathologic study of type 1 cases treated at a single institution. Int J Gynecol Cancer 2006;16:1212–5.
Sanchez A, Rodríguez D, Allard CB, et al. Primary genitourinary melanoma: epidemiology and disease-specific survival in a large population-based cohort. Urol Oncol 2016;34:166.e7–166.e14.
Gungor T, Altinkaya SO, Ozat M, et al. Primary malignant melanoma of the female genital tract. Taiwan J Obstet Gynecol 2009;48:169–75.
Behbahani S, Malerba S, Warren CJ, et al. Melanoma in situ and invasive melanoma of the vulva: an analysis of the National Cancer Database. J Am Acad Dermatol 2021;84:1744–9.
Mert I, Semaan A, Winer I, et al. Vulvar/vaginal melanoma: an updated surveillance epidemiology and end results database review, comparison with cutaneous melanoma and significance of racial disparities. Int J Gynecol Cancer 2013;23:1118–25.
Faber MT, Sand FL, Albieri V, et al. Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva. Int J Cancer 2017;141:1161–9.
Rakislova N, Saco A, Sierra A, et al. Role of human papillomavirus in vulvar cancer. Adv Anat Pathol 2017;24:201–14.
Thuijs NB, Berkhof J, Özer M, et al. DNA methylation markers for cancer risk prediction of vulvar intraepithelial neoplasia. Int J Cancer 2021;148:2481–8.
Swarts DRA, Voorham QJM, van Splunter AP, et al. Molecular heterogeneity in human papillomavirus-dependent and -independent vulvar carcinogenesis. Cancer Med 2018;7:4542–53.
Bleeker MCG, Visser PJ, Overbeek LIH, et al. Lichen sclerosus: incidence and risk of vulvar squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2016;25:1224–30.
del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology 2013;62:161–75.
Nooij LS, Ter Haar NT, Ruano D, et al. Genomic characterization of vulvar (pre)cancers identifies distinct molecular subtypes with prognostic significance. Clin Cancer Res 2017;23:6781–9.
Watkins JC, Howitt BE, Horowitz NS, et al. Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. Mod Pathol 2017;30:448–58.
Tessier-Cloutier B, Kortekaas KE, Thompson E, et al. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Mod Pathol 2020;33:1595–605.
Fatalska A, Rusetska N, Bakuła-zalewska E. Inflammatory proteins HMGA2 and PRTN3 as drivers of vulvar squamous cell carcinoma progression. Cancers 2021;13:1–16.
Hoang LN, Park KJ, Soslow RA, et al. Squamous precursor lesions of the vulva: current classification and diagnostic challenges. Pathology 2016;48:291–302.
Regauer S, Reich O, Eberz B. Vulvar cancers in women with vulvar lichen planus: a clinicopathological study. J Am Acad Dermatol 2014;71:698–707.
Halonen P, Jakobsson M, Heikinheimo O, et al. Cancer risk of lichen planus: a cohort study of 13,100 women in Finland. Int J Cancer 2018;142:18–22.
Lewis FM, Harrington CI. Squamous cell carcinoma arising in vulval lichen planus. Br J Dermatol 1994;131:703–5.
Zaki I, Dalziel KL, Solomonsz FA, et al. The under-reporting of skin disease in association with squamous cell carcinoma of the vulva. Clin Exp Dermatol 1996;21:334–7.
Jones RW, Rowan DM, Kirker J, et al. Vulval lichen planus: progression of pseudoepitheliomatous hyperplasia to invasive vulval carcinomas. BJOG 2001;108:665–6.
Derrick EK, Ridley CM, Kobza-Black A, et al. A clinical study of 23 cases of female anogenital carcinoma. Br J Dermatol 2000;143:1217–23.
Regauer S, Reich O, Beham-Schmid C. Monoclonal γ-T-cell receptor rearrangement in vulvar lichen sclerosus and squamous cell carcinomas. Am J Pathol 2002;160:1035–45.
Regauer S. Extramammary Paget’s disease-a proliferation of adnexal origin? Histopathology 2006;48:723–9.
Reich O, Liegl B, Tamussino K, et al. p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease. Mod Pathol 2005;18:354–7.
Horn L-C, Purz S, Krumpe C, et al. COX-2 and Her-2/neu are overexpressed in Paget’s disease of the vulva and the breast: results of a preliminary study. Arch Gynecol Obstet 2008;277:135–8.
Tessier-Cloutier B, Asleh-Aburaya K, Shah V, et al. Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas. Histopathology 2017;71:446–52.
Garganese G, Inzani F, Mantovani G, et al. The vulvar immunohistochemical panel (VIP) project: molecular profiles of vulvar Paget's disease. J Cancer Res Clin Oncol 2019;145:2211–25.
Kang Z, Xu F, Zhang Q-an, et al. Oncogenic mutations in extramammary Paget's disease and their clinical relevance. Int J Cancer 2013;132:824–31.
Konstantinova AM, Shelekhova KV, Imyanitov EN, et al. Study of selected BRCA1, BRCA2, and PIK3CA mutations in benign and malignant lesions of anogenital mammary-like glands. Am J Dermatopathol 2017;39:358–62.
Lee M-W, Jee K-J, Gong G-Y, et al. Comparative genomic hybridization in extramammary Paget’s disease. Br J Dermatol 2005;153:290–4.
Gadducci A, Carinelli S, Guerrieri ME, et al. Melanoma of the lower genital tract: prognostic factors and treatment modalities. Gynecol Oncol 2018;150:180–9.
Preti M, Igidbashian S, Costa S, et al. VIN usual type-from the past to the future. Ecancermedicalscience 2015;9:531.
van Beurden M, van der Vange N, de Craen AJ, et al. Normal findings in vulvar examination and vulvoscopy. Br J Obstet Gynaecol 1997;104:320–4.
Albuquerque A, Rios E, Schmitt F. Recommendations favoring anal cytology as a method for anal cancer screening: a systematic review. Cancers 2019;11. doi:10.3390/cancers11121942. [Epub ahead of print: 04 12 2019].
doi: 10.3390/cancers11121942
Preti M, Scurry J, Marchitelli CE, et al. Vulvar intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol 2014;28:1051–62.
Hart WR. Vulvar intraepithelial neoplasia: historical aspects and current status. Int J Gynecol Pathol 2001;20:16–30.
Jin C, Liang S. Differentiated vulvar intraepithelial neoplasia: a brief review of clinicopathologic features. Arch Pathol Lab Med 2019;143:768–71.
Preti M, Bucchi L, Ghiringhello B, et al. Risk factors for unrecognized invasive carcinoma in patients with vulvar high-grade squamous intraepithelial lesion at vulvoscopy-directed biopsy. J Gynecol Oncol 2017;28:e27.
Maclean AB. Vulval cancer: prevention and screening. Best Pract Res Clin Obstet Gynaecol 2006;20:379–95.
Lynch PJ, Moyal-Barracco M, Scurry J. ISSVD terminology and classification of vulvar dermatological disorders: an approach to clinical diagnosis. J Low Genit Tract Dis 2011;2012:339–44.
Preti M, Micheletti L, Massobrio M, et al. Vulvar Paget disease: one century after first reported. J Low Genit Tract Dis 2003;7:122–35.
Terlou A, Blok LJ, Helmerhorst TJM, et al. Premalignant epithelial disorders of the vulva: squamous vulvar intraepithelial neoplasia, vulvar Paget’s disease and melanoma in situ. Acta Obstet Gynecol Scand 2010;89:741–8.
Sadownik LA, Crawford RI. Post-surgical treatment of melanoma in situ of the vulva with imiquimod. J Obstet Gynaecol Can 2010;32:771–4.
Venkatesan A. Pigmented lesions of the vulva. Dermatol Clin 2010;28:795–805.
Preti M, Mezzetti M, Robertson C, et al. Inter-observer variation in histopathological diagnosis and grading of vulvar intraepithelial neoplasia: results of a European collaborative study. BJOG 2000;107:594–9.
Dasgupta S, de Jonge E, Van Bockstal MR. Histological interpretation of differentiated vulvar intraepithelial neoplasia (dVIN) remains challenging—observations from a bi-national ring-study. Virchows Arch (Published Online First: 8 March 2021).
Singh N, Leen SL, Han G, et al. Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss. Am J Surg Pathol 2015;39:52–60.
van de Nieuwenhof HP, Bulten J, Hollema H, et al. Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma. Mod Pathol 2011;24:297–305.
Heller DS, Day T, Allbritton JI, et al. Diagnostic criteria for differentiated vulvar intraepithelial neoplasia and vulvar aberrant maturation. J Low Genit Tract Dis 2021;25:57–70.
Day T, Wilkinson E, Rowan D, et al. Clinicopathologic diagnostic criteria for vulvar lichen planus. J Low Genit Tract Dis 2020;24:317–29.
Dasgupta S, Ewing-Graham PC, Swagemakers SMA, et al. Precursor lesions of vulvar squamous cell carcinoma – histology and biomarkers: a systematic review. Crit Rev Oncol Hematol 2020;147:102866.
Konstantinova AM, Kazakov DV. Extramammary Paget disease of the vulva. Semin Diagn Pathol 2021;38:62–70.
Brown HM, Wilkinson EJ. Uroplakin-III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma. Hum Pathol 2002;33:545–8.
Liao X, Liu X, Fan X, et al. Perianal Paget’s disease: a clinicopathological and immunohistochemical study of 13 cases. Diagn Pathol 2020;15:29.
Parra-Medina R, Morales SD. Diagnostic utility of epithelial and melanocitic markers with double sequential immunohistochemical staining in differentiating melanoma in situ from invasive melanoma. Ann Diagn Pathol 2017;26:70–4.
Terlou A, van Seters M, Kleinjan A, et al. Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia. Int J Cancer 2010;127:2831–40.
van Seters M, Beckmann I, Heijmans-Antonissen C, et al. Disturbed patterns of immunocompetent cells in usual-type vulvar intraepithelial neoplasia. Cancer Res 2008;68:6617–22.
Singh K, Yeo Y, Honest H, et al. Antigen processing and correlation with immunological response in vulval intraepithelial neoplasia–a study of CD1a, CD54 and LN3 expression. Gynecol Oncol 2006;102:489–92.
van Esch EMG, van Poelgeest MIE, Trimbos JBMZ, et al. Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV-induced vulvar neoplasia. Int J Cancer 2015;136:E85–94.
Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269–74.
Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 2001;61:192–6 http://www.ncbi.nlm.nih.gov/pubmed/11196160 .
Abdulrahman Z, Kortekaas KE, De Vos Van Steenwijk PJ, et al. The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy. Expert Opin Biol Ther 2018;18:1223–33.
Kenter GG, Welters MJP, Valentijn ARPM, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838–47.
van Poelgeest MIE, Welters MJP, Vermeij R, et al. Vaccination against oncoproteins of HPV16 for noninvasive vulvar/vaginal lesions: lesion clearance is related to the strength of the T-cell response. Clin Cancer Res 2016;22:2342–50.
Press JZ, Allison KH, Garcia R, et al. FOXP3+ regulatory T-cells are abundant in vulvar Paget’s disease and are associated with recurrence. Gynecol Oncol 2011;120:296–9.
Fujimura T, Kambayashi Y, Hidaka T, et al. Comparison of Foxp3+ regulatory T cells and CD163+ macrophages in invasive and non-invasive extramammary Paget's disease. Acta Derm Venereol 2012;92:625–8.
van der Linden M, van Esch E, Bulten J, et al. The immune cell infiltrate in the microenvironment of vulvar Paget disease. Gynecol Oncol 2018;151:453–9.
Lawrie TA, Nordin A, Chakrabarti M, et al. Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia. Cochrane Database Syst Rev 2016;2016.
Chin S, Scurry J, Bradford J, et al. Association of topical corticosteroids with reduced vulvar squamous cell carcinoma recurrence in patients with vulvar lichen sclerosus. JAMA Dermatol 2020;156:813–4.
Te Grootenhuis NC, Pouwer A-FW, de Bock GH, et al. Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: a systematic review. Gynecol Oncol 2018;148:622–31.
Yap JKW, Fox R, Leonard S, et al. Adjacent lichen sclerosis predicts local recurrence and second field tumour in women with vulvar squamous cell carcinoma. Gynecol Oncol 2016;142:420–6.
Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol 2015;151:1061–7.
Bigby SM, Eva LJ, Fong KL. The natural history of vulvar intraepithelial neoplasia, differentiated type: evidence for progression and diagnostic challenges. Int J Gynecol Pathol 2016;35:574–84.
Regauer S. Residual anogenital lichen sclerosus after cancer surgery has a high risk for recurrence: a clinicopathological study of 75 women. Gynecol Oncol 2011;123:289–94.
Athavale R, Naik R, Godfrey KA, et al. Vulvar intraepithelial neoplasia–the need for auditable measures of management. Eur J Obstet Gynecol Reprod Biol 2008;137:97–102.
Bradbury M, Cabrera S, García-Jiménez A. Vulvar intraepithelial neoplasia: clinical presentation, management and outcomes in women infected with HIV. Aids 2016;30:859–67.
Bruchim I, Gotlieb WH, Mahmud S, et al. HPV-related vulvar intraepithelial neoplasia: outcome of different management modalities. Int J Gynecol Obstet 2007;99:23–7.
Fehr MK, Baumann M, Mueller M, et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. J Gynecol Oncol 2013;24:236–41.
Frega A, Sopracordevole F, Scirpa P, et al. The re-infection rate of high-risk HPV and the recurrence rate of vulvar intraepithelial neoplasia (VIN) usual type after surgical treatment. Med Sci Monit 2011;17:CR532–5.
Gentile M, Bianchi P, Sesti F, et al. Adjuvant topical treatment with imiquimod 5% after excisional surgery for VIN 2/3. Eur Rev Med Pharmacol Sci 2014;18:2949–52 http://www.ncbi.nlm.nih.gov/pubmed/25339491 .
Hillemanns P, Wang X, Staehle S, et al. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol 2006;100:271–5.
Kesterson JP, Lele S. Vulvar intraepithelial neoplasia 3 in women less than 35 years. J Low Genit Tract Dis 2009;13:196–9.
Kushnir CL, Fleury AC, Hill MC, et al. The use of argon beam coagulation in treating vulvar intraepithelial neoplasia III: a retrospective review. Gynecol Oncol 2013;131:386–8.
Leufflen L, Baermann P, Rauch P, et al. Treatment of vulvar intraepithelial neoplasia with CO(2) laser vaporization and excision surgery. J Low Genit Tract Dis 2013;17:446–51.
Massad LS, Xie X, Darragh T. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol 2011;118:831–9.
Miller BE. Vulvar intraepithelial neoplasia treated with cavitational ultrasonic surgical aspiration. Gynecol Oncol 2002;85:114–8.
Polterauer S, Catharina Dressler A, Grimm C, et al. Accuracy of preoperative vulva biopsy and the outcome of surgery in vulvar intraepithelial neoplasia 2 and 3. Int J Gynecol Pathol 2009;28:559–62.
Ribeiro F, Figueiredo A, Paula T. Vulvar intraepithelial neoplasia: evaluation of treatment modalities. J Low Genit Tract Dis 2012;16:313–7.
Satmary W, Holschneider CH, Brunette LL, et al. Vulvar intraepithelial neoplasia: risk factors for recurrence. Gynecol Oncol 2018;148:126–31.
Sykes P, Smith N, McCormick P, et al. High-grade vulval intraepithelial neoplasia (VIN 3): a retrospective analysis of patient characteristics, management, outcome and relationship to squamous cell carcinoma of the vulva 1989-1999. Aust N Z J Obstet Gynaecol 2002;42:75–80.
van Esch EMG, Dam MCI, Osse MEM, et al. Clinical characteristics associated with development of recurrence and progression in usual-type vulvar intraepithelial neoplasia. Int J Gynecol Cancer 2013;23:1476–83.
Vlastos A-T, Levy LB, Malpica A, et al. Loop electrosurgical excision procedure in vulvar intraepithelial neoplasia treatment. J Low Genit Tract Dis 2002;6:232–8.
von Gruenigen VE, Gibbons HE, Gibbins K, et al. Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstet Gynecol 2007;109:942–7.
Wallbillich JJ, Rhodes HE, Milbourne AM, et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecol Oncol 2012;127:312–5.
Gu Y, Zhu L, Li X, et al. Surgical treatment of usual type vulvar intraepithelial neoplasia: a study at three academic hospitals. Chin Med J 2014;127:784–6.
Zawislak AA, Price JH, Dobbs SP, et al. Contemporary experience with the management of vulval intraepithelial neoplasia in Northern Ireland. Int J Gynecol Cancer 2006;16:780–5.
de Witte CJ, van de Sande AJM, van Beekhuizen HJ, et al. Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a review. Gynecol Oncol 2015;139:377–84.
van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J Reprod Med 2002;47:701–5 http://www.ncbi.nlm.nih.gov/pubmed/12380448 .
Mathiesen O, Buus S, Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. Gynecol Oncol 2007;107:219–22.
van Seters M, van Beurden M, ten Kate FJW, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008;358:1465–73.
Terlou A, van Seters M, Ewing PC, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol 2011;121:157–62.
Tristram A, Hurt CN, Madden T, et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT 3 VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2014;15:1361–8.
Hurt CN, Jones SEF, Madden T-A, et al. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN). BJOG 2018;125:1171–7.
Jones SEF, Hibbitts S, Hurt CN, et al. Human papillomavirus DNA methylation predicts response to treatment using cidofovir and imiquimod in vulval intraepithelial neoplasia 3. Clin Cancer Res 2017;23:5460–8.
Westermann C, Fischer A, Clad A. Treatment of vulvar intraepithelial neoplasia with topical 5% imiquimod cream. Int J Gynecol Obstet 2013;120:266–70.
Le T, Menard C, Hicks-Boucher W, et al. Final results of a phase 2 study using continuous 5% imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. Gynecol Oncol 2007;106:579–84.
Fehr MK, Hornung R, Degen A, et al. Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Lasers Surg Med 2002;30:273–9.
Zawislak A, Donnelly RF, McCluggage WG, et al. Clinical and immunohistochemical assessment of vulval intraepithelial neoplasia following photodynamic therapy using a novel bioadhesive patch-type system loaded with 5-aminolevulinic acid. Photodiagnosis Photodyn Ther 2009;6:28–40.
Jones RW, MacLean AB. Re: ‘Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients.’. Gynecol Oncol 2006;101:371–2.
Buchanan TR, Zamorano AS, Massad LS, et al. Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: a 6 year follow-up study. Gynecol Oncol 2019;155:88–92.
Ait Menguellet S, Collinet P, Debarge VH, et al. Management of multicentric lesions of the lower genital tract. Eur J Obstet Gynecol Reprod Biol 2007;132:116–20.
Kuroki LM, Frolova AI, Wu N, et al. Yield of cytology surveillance after high-grade vulvar intraepithelial neoplasia or cancer. J Low Genit Tract Dis 2017;21:193–7.
Cai Y, Sheng W, Xiang L, et al. Primary extramammary Paget’s disease of the vulva: the clinicopathological features and treatment outcomes in a series of 43 patients. Gynecol Oncol 2013;129:412–6.
De Magnis A, Checcucci V, Catalano C, et al. Vulvar Paget disease: a large single-centre experience on clinical presentation, surgical treatment, and long-term outcomes. J Low Genit Tract Dis 2013;17:104–10.
Black D, Tornos C, Soslow RA, et al. The outcomes of patients with positive margins after excision for intraepithelial Paget’s disease of the vulva. Gynecol Oncol 2007;104:547–50.
Liu G, Yuan B, Wang Y, et al. Clinicopathologic study of vulvar Paget’s disease in China. J Low Genit Tract Dis 2014;18:281–4.
Borghi C, Bogani G, Ditto A, et al. Invasive Paget disease of the vulva. Int J Gynecol Cancer 2018;28:176–82.
van der Linden M, Meeuwis K, van Hees C, et al. The Paget trial: a multicenter, observational cohort intervention study for the clinical efficacy, safety, and immunological response of topical 5% imiquimod cream for vulvar Paget disease. JMIR Res Protoc 2017;6:e178.
Marchitelli C, Peremateu MS, Sluga MC, et al. Treatment of primary vulvar Paget disease with 5% imiquimod cream. J Low Genit Tract Dis 2014;18:347–50.
Fontanelli R, Papadia A, Martinelli F, et al. Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease. Gynecol Oncol 2013;130:90–4.
Kingston NJ, Jones RW, Baranyai J. Recurrent primary vulvovaginal malignant melanoma arising in melanoma in situ the natural history of lesions followed for 23 years. Int J Gynecol Cancer 2004;14:628–32.
Bartoli C, Bono A, Clemente C, et al. Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer 1996;77:888–92.
Heinzelmann-Schwarz VA, Nixdorf S, Valadan M, et al. A clinicopathological review of 33 patients with vulvar melanoma identifies c-kit as a prognostic marker. Int J Mol Med 2014;33:784–94.
Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 2004;292:2771–6.
Tran KT, Wright NA, Cockerell CJ. Biopsy of the pigmented lesion—when and how. J Am Acad Dermatol 2008;59:852–71.
ACOG practice Bulletin No. 93: diagnosis and management of vulvar skin disorders. Obstet Gynecol 2008;111:1243–54.
Moxley KM, Fader AN, Rose PG, et al. Malignant melanoma of the vulva: an extension of cutaneous melanoma? Gynecol Oncol 2011;122:612–7.
Garland SM, Joura EA, Ault KA, et al. Human papillomavirus genotypes from vaginal and vulvar intraepithelial neoplasia in females 15-26 years of age. Obstet Gynecol 2018;132:261–70.
Giuliano AR, Joura EA, Garland SM, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol 2019;154:110–7.
Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693–702.
Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401.
Ghelardi A, Marrai R, Bogani G, et al. Surgical treatment of vulvar HSIL: adjuvant HPV vaccine reduces recurrent disease. Vaccines 2021;9. doi:10.3390/vaccines9020083. [Epub ahead of print: 25 01 2021].
doi: 10.3390/vaccines9020083
Micheletti L, Preti M, Radici G, et al. Vulvar lichen sclerosus and neoplastic transformation: a retrospective study of 976 cases. J Low Genit Tract Dis 2016;20:180–3.
Corazza M, Borghi A, Gafà R, et al. Risk of vulvar carcinoma in women affected with lichen sclerosus: results of a cohort study. JDDG J Ger Soc Dermatology 2019;17:1069–71.
Lewis FM, Tatnall FM, Velangi SS, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol 2018;178:839–53.
Nerantzoulis I, Grigoriadis T, Michala L. Genital lichen sclerosus in childhood and adolescence-a retrospective case series of 15 patients: early diagnosis is crucial to avoid long-term sequelae. Eur J Pediatr 2017;176:1429–32.
Brickman C, Palefsky JM. Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. Curr HIV/AIDS Rep 2015;12:6–15.
Konopnicki D, De Wit S, Clumeck N. HPV and HIV coinfection: a complex interaction resulting in epidemiological, clinical and therapeutic implications. Future Virol 2013;8:903–15.
Smith AJB, Varma S, Rositch AF, et al. Gynecologic cancer in HIV-positive women: a systematic review and meta-analysis. Am J Obstet Gynecol 2019;221:194–207.
Ayakannu T, Murugesu S, Taylor AH, et al. The impact of focality and centricity on vulvar intraepithelial neoplasia on disease progression in HIV+ patients: a 10-year retrospective study. Dermatology 2019;235:327–33.
Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002;359:108–13.
Toby M, Conway K, Sethi G, et al. Usual vulval intraepithelial neoplasia in HIV-positive women – a case series. Int J STD AIDS 2016;27:1253–6.
Blitz S, Baxter J, Raboud J, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis 2013;208:454–62.
Massad LS, Silverberg MJ, Springer G, et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol 2004;190:1241–8.
Franzetti M, Adorni F, Parravicini C. Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART. J Acquir Immune Defic Syndr 2013;62:414–20.
Hinten F, Hilbrands LB, Meeuwis KAP, et al. Reactivation of latent HPV infections after renal transplantation. Am J Transplant 2017;17:1563–73.
Meeuwis KAP, Hilbrands LB, IntHout J, et al. Cervicovaginal HPV infection in female renal transplant recipients: an observational, self-sampling based, cohort study. Am J Transplant 2015;15:723–33.
Reinholdt K, Thomsen LT, Dehlendorff C, et al. Human papillomavirus-related anogenital premalignancies and cancer in renal transplant recipients: a Danish nationwide, registry-based cohort study. Int J Cancer 2020;146:2413–22.
Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59–67.
Preti M, Rotondo JC, Holzinger D, et al. Role of human papillomavirus infection in the etiology of vulvar cancer in Italian women. Infect Agent Cancer 2020;15:20.
Meeuwis KAP, Melchers WJG, Bouten H, et al. Anogenital malignancies in women after renal transplantation over 40 years in a single center. Transplantation 2012;93:914–22.
Chin-Hong PV. Human papillomavirus in kidney transplant recipients. Semin Nephrol 2016;36:397–404.
Chin-Hong PV, Reid GE; AST Infectious Diseases Community of Practice. Human papillomavirus infection in solid organ transplant recipients: guidelines from the American Society of Transplantation infectious diseases community of practice. Clin Transplant 2019;33:e13590.
Preti M, Selk A, Stockdale C, et al. Knowledge of vulvar anatomy and self-examination in a sample of Italian women. J Low Genit Tract Dis 2021;25:166–71.
Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014;22.
Conn VS, Ruppar TM. Medication adherence outcomes of 771 intervention trials: systematic review and meta-analysis. Prev Med 2017;99:269–76.
Höckel M, Dornhöfer N. Vulvovaginal reconstruction for neoplastic disease. Lancet Oncol 2008;9:559–68.
Micheletti L, Haefner H, Zalewski K, et al. The International Society for the Study of Vulvovaginal Disease Surgical Oncological Procedure Definitions Committee “Surgical Terminology for Vulvar Cancer Treatment”. J Low Genit Tract Dis 2020;24:62–8.
Likes WM, Stegbauer C, Tillmanns T, et al. Correlates of sexual function following vulvar excision. Gynecol Oncol 2007;105:600–3.
Salgarello M, Farallo E, Barone-Adesi L, et al. Flap algorithm in vulvar reconstruction after radical, extensive vulvectomy. Ann Plast Surg 2005;54:184–90.
Reid R. Local and distant skin flaps in the reconstruction of vulvar deformities. Am J Obstet Gynecol 1997;177:1372–84.
Julian CG, Callison J, Woodruff JD. Plastic management of extensive vulvar defects. Obstet Gynecol 1971;38:193–8 http://www.ncbi.nlm.nih.gov/pubmed/4327054 .
Narayansingh GV, Cumming GP, Parkin DP, et al. Flap repair: an effective strategy for minimising sexual morbidity associated with the surgical management of vulval intra epithelial neoplasia. J R Coll Surg Edinb 2000;45:81–4.
Lucich EA, Rendon JL, Valerio IL. Advances in addressing full-thickness skin defects: a review of dermal and epidermal substitutes. Regen Med 2018;13:443–56.
Terlou A, Hage JJ, van Beurden M. Skinning clitorectomy and skin replacement in women with vulvar intra-epithelial neoplasia. J Plast Reconstr Aesthetic Surg 2009;62:341–5.
Rutledge F, Sinclair M. Treatment of intraepithelial carcinoma of the vulva by skin excision and graft. Am J Obstet Gynecol 1968;102:806–18.
Ayhan A, Tancer ZS, Doǧan L. Skinning vulvectomy for the treatment of vulvar intraepithelial neoplasia 2-3: a study of 21 cases. Eur J Gynaecol Oncol 1998;19:508–10 http://www.ncbi.nlm.nih.gov/pubmed/9863927 .
Caglar H, Delgado G, Hreshchyshyn MM. Partial and total skinning vulvectomy in treatment of carcinoma in situ of the vulva. Obstet Gynecol 1986;68:504–7.
Rettenmaier MA, Berman ML, DiSaia PJ. Skinning vulvectomy for the treatment of multifocal vulvar intraepithelial neoplasia. Obstet Gynecol 1987;69:484–50.
Hage J, Beurden M, van BM. Reconstruction of acquired perineovulvar defects: a proposal of sequence. Semin Plast Surg 2011;25:148–54.
Tan B-K, Kang GC-W, Tay EH, et al. Subunit principle of vulvar reconstruction: algorithm and outcomes. Arch Plast Surg 2014;41:379–86.
Negosanti L, Sgarzani R, Fabbri E, et al. Vulvar reconstruction by perforator flaps: algorithm for flap choice based on the topography of the defect. Int J Gynecol Cancer 2015;25:1322–7.
Gentileschi S, Servillo M, Garganese G, et al. Surgical therapy of vulvar cancer: how to choose the correct reconstruction? J Gynecol Oncol 2016;27:e60.
Weinstein RS, Krupinski EA, Doarn CR. Clinical examination component of telemedicine, telehealth, mHealth, and connected health medical practices. Med Clin North Am 2018;102:533–44.
Ferris DG, Macfee MS, Miller JA, et al. The efficacy of telecolposcopy compared with traditional colposcopy. Obstet Gynecol 2002;99:248–54.
Ekeland AG, Bowes A, Flottorp S. Effectiveness of telemedicine: a systematic review of reviews. Int J Med Inform 2010;79:736–71.
Kobleder A, Nikolic N, Hechinger M, et al. Perceived health-related quality of life in women with vulvar neoplasia: a cross sectional study. Int J Gynecol Cancer 2016;26:1313–9.